| Literature DB >> 33716307 |
Nouman Rasool1, Farkhanda Yasmin2, Shalini Sahai3, Waqar Hussain1,4, Hadiqa Inam5, Arooj Arshad5.
Abstract
Humans around the globe have been severely affected by SARS-CoV-2 and no treatment has yet been authorized for the treatment of this severe condition brought by COVID-19. Here, an in silico research was executed to elucidate the inhibitory potential of selected thiazolides derivatives against SARS-CoV-2 Protease (Mpro) and Methyltransferase (MTase). Based on the analysis; 4 compounds were discovered to have efficacious and remarkable results against the proteins of the interest. Primarily, results obtained through this study not only allude these compounds as potential inhibitors but also pave the way for in vivo and in vitro validation of these compounds.Entities:
Keywords: COVID-19; MTase; Mpro; SARS-CoV-2; Thiazolide Derivatives
Year: 2021 PMID: 33716307 PMCID: PMC7936854 DOI: 10.1016/j.cplett.2021.138463
Source DB: PubMed Journal: Chem Phys Lett ISSN: 0009-2614 Impact factor: 2.328
Fig. 1Flowchart of methodology.
ADMET Properties of selected Thiazolide Derivates.
| Compounds | ESOL Class | GI Absorption | BBB Penetration | Lipinski violations | Toxicity | Carcinogenicity |
|---|---|---|---|---|---|---|
| Comp1 | Soluble | High | No | 0 | Non-Toxic | Non-Carcinogenic |
| Comp2 | Soluble | High | No | 0 | Non-Toxic | Non-Carcinogenic |
| Comp3 | Soluble | High | No | 0 | Non-Toxic | Non-Carcinogenic |
| Comp4 | Soluble | High | No | 3 | Non-Toxic | Non-Carcinogenic |
| Comp5 | Soluble | High | No | 0 | Non-Toxic | Non-Carcinogenic |
| Comp6 | Soluble | High | No | 2 | Non-Toxic | Non-Carcinogenic |
| Comp7 | Soluble | High | No | 3 | Non-Toxic | Non-Carcinogenic |
| Comp8 | Soluble | High | No | 0 | Non-Toxic | Non-Carcinogenic |
| Comp9 | Soluble | High | No | 0 | Non-Toxic | Non-Carcinogenic |
| Comp10 | Soluble | High | No | 0 | Non-Toxic | Non-Carcinogenic |
| Comp11 | Soluble | High | No | 0 | Non-Toxic | Non-Carcinogenic |
| Comp12 | Soluble | High | No | 0 | Non-Toxic | Non-Carcinogenic |
| Comp13 | Soluble | High | No | 0 | Non-Toxic | Non-Carcinogenic |
| Comp14 | Soluble | High | No | 0 | Non-Toxic | Non-Carcinogenic |
| Comp15 | Soluble | High | No | 0 | Non-Toxic | Non-Carcinogenic |
| Comp16 | Soluble | High | No | 0 | Non-Toxic | Non-Carcinogenic |
| Comp17 | Soluble | High | No | 0 | Non-Toxic | Non-Carcinogenic |
| Comp18 | Soluble | High | No | 0 | Non-Toxic | Non-Carcinogenic |
| Comp19 | Soluble | High | No | 0 | Non-Toxic | Non-Carcinogenic |
Thus, due to Lipinski’s rules violations, Comp4, Comp6 and Comp7 were excluded from docking.
Binding affinities and Ki values for docking of screened compounds against MTase and Mpro.
| Compound Name | MTase | Mpro | ||
|---|---|---|---|---|
| Binding Energies (kcal/mole) | Ki (µM) | Binding Energies (kcal/mole) | Ki (µM) | |
| Comp1 | −6.8 | 10.23 | −6.7 | 12.12 |
| Comp2 | −7.0 | 7.30 | −6.3 | 23.82 |
| Comp3 | −6.4 | 20.12 | −6.0 | 39.54 |
| Comp5 | −6.9 | 8.64 | −6.0 | 39.54 |
| Comp8 | −6.6 | 14.35 | −6.8 | 10.23 |
| Comp9 | −7.1 | 6.16 | −6.6 | 14.35 |
| Comp10 | −6.8 | 10.23 | −6.2 | 28.20 |
| Comp11 | −6.5 | 16.99 | −6.5 | 16.99 |
| Comp12 | −7.0 | 7.30 | −6.4 | 20.12 |
| Comp13 | −7.2 | 5.21 | −6.1 | 33.40 |
| Comp14 | −7.1 | 6.16 | −6.4 | 20.12 |
| Comp15 | −6.9 | 8.64 | −6.6 | 14.35 |
| Comp16 | −7.1 | 6.16 | −7.5 | 3.14 |
| Comp17 | −7.2 | 5.21 | −6.7 | 12.12 |
| Comp18 | −7.0 | 7.30 | −6.4 | 20.12 |
| Comp19 | −6.5 | 16.99 | −6.7 | 12.12 |
Fig. 2Thiazolide Derivates displaying promising results against targeted receptor: methyltransferase with binding affinities ≥−6.5 kcal/mol. (a) Comp13 (b) Comp17 (c) Comp9 (d) Comp14 (e) Comp16 (f) Comp2 (g) Comp12 (h) Comp18 (i) Comp5 (j) Comp15 (k) Comp1 (l) Comp10 (m) Comp8 (n) Comp11 (o) Comp19.
Fig. 3Thiazolide Derivates displaying promising results against targeted receptor: main protease with binding affinities ≥−6.5 kcal/mol. (a) Comp16 (b) Comp8 (c) Comp1 (d) Comp17 (e) Comp19 (f) Comp9 (g) Comp15 (h) Comp11.
DFT results for compounds showing binding affinity ≥ threshold value against Methyltransferase.
| Compound | ELUMO (kcal/mol) | EHOMO (kcal/mol) | Band energy gap (ΔE) (kcal/mol) |
|---|---|---|---|
| −0.274 | −0.389 | 0.114 | |
| −0.280 | −0.395 | 0.116 | |
| −0.262 | −0.380 | 0.118 | |
| −0.275 | −0.395 | 0.120 | |
| −0.266 | −0.390 | 0.124 | |
| −0.293 | −0.418 | 0.125 | |
| −0.303 | −0.428 | 0.125 | |
| −0.237 | −0.369 | 0.132 | |
| −0.242 | −0.375 | 0.133 | |
| −0.273 | −0.417 | 0.144 | |
| −0.302 | −0.449 | 0.148 | |
| −0.235 | −0.386 | 0.151 | |
| −0.281 | −0.432 | 0.151 | |
| −0.258 | −0.409 | 0.151 | |
| −0.256 | −0.415 | 0.159 |
DFT results for compounds showing binding affinity ≥ threshold value against Main Protease.
| Compound | ELUMO (kcal/mol) | EHOMO (kcal/mol) | Band energy gap (ΔE) (kcal/mol) |
|---|---|---|---|
| −0.236 | −0.351 | 0.115 | |
| −0.274 | −0.391 | 0.116 | |
| −0.304 | −0.421 | 0.118 | |
| −0.288 | −0.407 | 0.118 | |
| −0.238 | −0.359 | 0.120 | |
| −0.273 | −0.401 | 0.127 | |
| −0.271 | −0.400 | 0.129 | |
| −0.251 | −0.382 | 0.131 |
Fig. 4Rg graph of experimental ligands with the targeted receptor (a) Mpro-Comp16 (b) Mpro -Comp8 (c) MTase-Comp13 (d) MTase-Comp17.
Average RMSD values for complexes of compounds passing threshold at temperature 300 K, 310 K, 320 K and 330 K.
| Complexes | Average RMSD at various temperatures (Å) | |||
|---|---|---|---|---|
| 300 K | 310 K | 320 K | 330 K | |
| Mpro-Comp16 | 0.75 | 0.98 | 1.15 | 1.30 |
| Mpro-Comp8 | 1.09 | 1.26 | 1.44 | 1.78 |
| MTase-Comp13 | 0.88 | 1.07 | 1.29 | 1.52 |
| MTase-Comp17 | 1.70 | 1.93 | 2.72 | 2.94 |
Fig. 53D interaction diagrams for (a) Mpro-Comp16 (b) Mpro -Comp8 (c) MTase-Comp13 (d) MTase-Comp17.